Passage Bio Stock Technical Analysis

PASG Stock  USD 7.73  -0.37  -4.57%   
As of the 13th of March 2026, Passage Bio indicates a price level of 7.73 per share. Price-based signals reflect Coefficient Of Variation of 9414.35, risk adjusted performance of 0.0174, and Semi Deviation of 6.83. The model quantifies price stability and directional movement. Relative volatility positioning is benchmarked against peers.

Passage Bio Momentum Analysis

Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as Passage, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to PassagePassage Bio's Momentum analyses are specifically helpful, as they help investors time the market using mark points where the market can reverse. The reversal spots are usually identified through divergence between price movement and momentum.

Analyst Consensus

Target PriceConsensus# of Analysts
30.8Strong Buy5Odds
The summary for Passage Bio includes current and past analyst recommendations. The view also includes average analyst consensus. The timing of analyst rating changes for Passage Bio matters as much as the direction. Rating upgrades issued after a large decline in Passage stock may reflect backward-looking analysis, while pre-emptive upgrades ahead of a catalyst tend to have stronger price impact.
Passage Analyst Advice Details
 Earnings Share
-14.35
 Return On Assets
-0.33
 Return On Equity
-1.14
Investors evaluate Passage Bio using market value and book value, each describing different facets of the business. Passage Bio's market capitalization is 25.98 M. A P/B ratio of 1.45 indicates the market values Passage Bio above its accounting book value. Enterprise value stands at 4.85 M. Value and price for Passage Bio are related but not identical, and they can diverge across cycles. Trading price represents the transaction level agreed by market participants.
Value and price for Passage Bio are related but not identical, and they can diverge across cycles. For Passage Bio, key inputs include a P/B ratio of 1.45, and ROE of -113.78%. Market price reflects the current exchange level formed by active bids and offers.

What if' Analysis

Running a what-if backtest on Passage Bio gives investors a practical way to test how changes in horizon, position size, or market timing might have affected the result. Used properly, this review helps investors decide whether Passage Bio's historical reward profile was stable enough to support the current thesis.
0.00
12/13/2025
 
No Change 0.00  0.0 
In 3 months and 1 day
 
03/13/2026
0.00
A  0.00  position in Passage Bio initiated on December 13, 2025 and held to today would record 0.00 in total gains. That corresponds to a 0.0% cumulative return in Passage Bio overall over 90 days. Passage Bio competes with or is related to NuCana PLC, MetaVia, Lisata Therapeutics, Allarity Therapeutics, CytoMed Therapeutics, Enlivex Therapeutics, and Cingulate. Peer context helps frame relative positioning. Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases More

Momentum Range Indicators for Passage Bio Overview

Upside/downside measures for Passage Bio frame directional pressure and range behavior. They compare current price to recent trend and sentiment readings.

Volatility and Risk Indicators for Passage Bio Overview

These indicators track Passage Bio's volatility and return range dynamics. The metrics rely on historical prices to describe variability over time.
Mean reversion in Passage Bio is more reliable over longer time horizons. Short-term deviations can persist and even widen before correcting, making position sizing and risk management critical.
Hype
Prediction
LowEstimatedHigh
0.397.8015.65
Details
Intrinsic
Valuation
LowRealHigh
5.6313.4821.33
Details
Naive
Forecast
LowNextHigh
0.115.4913.34
Details
5 Analysts
Consensus
LowTargetHigh
28.0330.8034.19
Details
Effective investment decisions about Passage Bio require competitive context. Benchmarking Passage Bio's against peers on earnings quality, growth consistency, and balance sheet strength can materially change the investment conclusion.

Technical Indicators

Passage Bio Backtested Returns

Passage Bio posts a slightly elevated risk exposure during the defined timeframe. It has a Sharpe Ratio of -0.0182, which indicates that -0.0182 units of return per unit of risk over the last 3 months. We identified twenty-seven technical indicators supporting this volatility profile. Please review metrics such as Semi Deviation of 6.83, risk-adjusted performance of 0.0174, and Coefficient Of Variation of 9414.35 to examine volatility dispersion. The firm maintains a market beta of 3.35, which implies a somewhat significant risk relative to the market. Market upswings tend to lift Passage Bio more than average, but downturns carry a proportionally larger impact on returns. At this point, Passage Bio has a negative expected return of -0.14%. Please make sure to verify Passage Bio's expected short fall, and the relationship between the value at risk and day median price, to decide if Passage Bio's performance from the past will be repeated at some point in the near future.
Auto-correlation
    
  -0.56  

Good reverse predictability

The autocorrelation profile for Passage Bio registers good reverse predictability between the two measured intervals. When lagged price patterns show consistency, they can serve as a partial input for modeling Passage Bio's near-term price behavior. A serial correlation of -0.56 indicates that roughly 56.0% of current Passage Bio price fluctuations can be explained by its historical price movements. Given that Passage Bio has negative autocorrelation for the selected time horizon, market participants may evaluate potential contrarian price behavior over comparable future intervals.
Correlation Coefficient-0.56
Spearman Rank Test-0.44
Residual Average0.0
Price Variance1.42
Technical analysis for Passage Bio evaluates price and volume patterns over time. Typical tools include moving averages, relative strength index, regressions, and price correlations.
This view emphasizes price behavior and trend signals over external narrative drivers. This framework highlights recurring patterns and trend context. More Info...

Technical Analysis

Indicator
Time Period
Execute Indicator
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Average True Range was developed by J. Welles Wilder in 1970s. It is one of components of the Welles Wilder Directional Movement indicators. The ATR is a measure of Passage Bio volatility. High ATR values indicate high volatility, and low values indicate low volatility.

Technical Analysis Methodology & Indicators

Technical analysis of Passage Bio evaluates price structure, momentum, and volatility clustering. Technical signals complement fundamental exposure context. Passage Bio has a market cap of 25.98 M, ROE of -113.78%.

The analytics block for Passage Bio relies on periodic company reporting and market reference feeds, with quality checks and normalization applied before rendering. Analyst inputs may be included when coverage is available. Timing can vary by data vendor.

This content is curated and reviewed by:

Rifka Kats - Member of Macroaxis Editorial Board

Passage Bio Technical Indicators

A technical review of Passage Bio can improve timing discipline by comparing momentum, reversal risk, and confirmation signals across several time horizons. The stronger process confirms one signal with others instead of reacting to one pattern in isolation.

March 13, 2026 Daily Trend Indicators

A technical review of Passage Bio can improve timing discipline by comparing momentum, reversal risk, and confirmation signals across several time horizons. The stronger process confirms one signal with others instead of reacting to one pattern in isolation.

Popular Tools for Passage Stock analysis

Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm